WallStSmart

MiMedx Group Inc (MDXG)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiMedx Group Inc generates 52382% more annual revenue ($389.42M vs $742,000). MDXG leads profitability with a 7.9% profit margin vs 0.0%. MDXG earns a higher WallStSmart Score of 52/100 (C-).

MDXG

Buy

52

out of 100

Grade: C-

Growth: 6.7Profit: 5.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 4.24

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDXGUndervalued (+88.8%)

Margin of Safety

+88.8%

Fair Value

$46.31

Current Price

$3.74

$42.57 discount

UndervaluedFair: $46.31Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDXG5 strengths · Avg: 9.2/10
EPS GrowthGrowth
99.5%10/10

Earnings expanding 99.5% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.2410/10

Safe zone — low bankruptcy risk

P/E RatioValuation
17.9x8/10

Attractively priced relative to earnings

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

MDXG4 concerns · Avg: 2.8/10
Market CapQuality
$533.23M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
7.9%3/10

7.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.882/10

Expensive relative to growth rate

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MDXG

The strongest argument for MDXG centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : MDXG

The primary concerns for MDXG are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

MDXG carries more volatility with a beta of 1.46 — expect wider price swings.

MDXG is growing revenue faster at -33.1% — sustainability is the question.

MDXG generates stronger free cash flow (1M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDXG scores higher overall (52/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiMedx Group Inc

HEALTHCARE · BIOTECHNOLOGY · USA

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?